SA
CERE

Scarborough Advisors’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Scarborough Advisors’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-200
Closed -$8.18K – 490
2024
Q2 		$8.18K Hold
200
– – ﹤0.01% 216
2024
Q1 		$8.45K Hold
200
– – ﹤0.01% 212
2023
Q4 		$8.48K Buy
+200
New +$5.75K ﹤0.01% 403

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Scarborough Advisors's CERE Position: Q3 2024 in Review

Scarborough Advisors sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 200 shares — an estimated $8.18K sold.

Scarborough Advisors first reported a position in CERE in Q4 2023 and held it in 3 quarters. The position peaked at $8.48K in Q4 2023. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Scarborough Advisors reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Scarborough Advisors sold 200 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $8.18K.
  • Scarborough Advisors first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2023 and held it in 3 quarters.
  • Scarborough Advisors's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $8.48K in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Scarborough Advisors's 13F filing for Q3 2024, filed 31 Oct 2024.